𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gene expression and association analyses of the phosphodiesterase 4B (PDE4B) gene in major depressive disorder in the Japanese population

✍ Scribed by Shusuke Numata; Jun-ichi Iga; Masahito Nakataki; Shin'Ya Tayoshi; Kyoko Taniguchi; Satsuki Sumitani; Masahito Tomotake; Toshihito Tanahashi; Mitsuo Itakura; Yoko Kamegaya; Masahiko Tatsumi; Akira Sano; Takashi Asada; Hiroshi Kunugi; Shu-ichi Ueno; Tetsuro Ohmori


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
170 KB
Volume
150B
Category
Article
ISSN
1552-4841

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The phosphodiesterase 4B (PDE4B) interacts with disrupted‐in‐schizophrenia 1 (DISC1), which is a known genetic risk factor for schizophrenia, bipolar disorder and major depressive disorder (MDD). PDE4B is also important in the regulation of cAMP signaling, a second messenger implicated in learning, memory, and mood. In this study, we determined mRNA expression levels of the PDE4B gene in the peripheral blood leukocytes of patients with MDD and control subjects (n = 33, each). Next we performed two‐stage case‐controlled association analyses (first set; case = 174, controls = 348; second set; case = 481, controls = 812) in the Japanese population to determine if the PDE4B gene is implicated in MDD. In the leukocytes, a significantly higher expression of the PDE4B mRNA was observed in the drug‐naïve MDD patients compared with control subjects (P < 0.0001) and the expression of the MDD patients significantly decreased after antidepressant treatment (P = 0.030). In the association analysis, we observed significant allelic associations of four SNPs (the most significant, rs472952; P = 0.002) and a significant haplotypic association (permutation P = 0.019) between the PDE4B gene and MDD in the first‐set samples. However, we could not confirm these significant associations in the following independent second‐set of samples. Our results suggest that the PDE4B gene itself does not link to MDD but the elevated mRNA levels of PDE4B might be implicated in the pathophysiology of MDD. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Association study of PDE4B gene variants
✍ Anna K. Kähler; Mona K. Otnæss; Katrine V. Wirgenes; Thomas Hansen; Erik G. Jöns 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Abstract The phosphodiesterase 4B (PDE4B), which is involved in cognitive function in animal models, is a candidate susceptibility gene for schizophrenia (SZ) and bipolar disorder (BP). Variations in __PDE4B__ have previously been associated with SZ, with a suggested gender‐specific effect. We h

Association analysis of 5HT transporter
✍ Saleem, Q.; Ganesh, S.; Vijaykumar, M.; Reddy, Y.C.J.; Brahmachari, S.K.; Jain, 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 8 KB 👁 2 views

A variable number tandem repeat (VNTR) polymorphism consisting of multiple copies of a 17-bp repeat in the second intron of the serotonin transporter gene (SERT) has been reported. Different alleles of this VNTR have been found to be associated with bipolar disorder and schizophrenia. These findings

Association studies of the CT repeat pol
✍ Hattori, Eiji ;Yamada, Kazuo ;Toyota, Tomoko ;Yoshitsugu, Kiyoshi ;Toru, Michio 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract The tetrapeptide of cholecystokinin (CCK), CCK‐4, is known to induce panic attacks in human subjects, while CCK‐8 is reported to have a therapeutic effect on schizophrenia symptoms. Recently, we have identified a novel microsatellite polymorphism in the 5′ upstream region of the CCK gen